Sugi Predict

Sugi Predict / Compounds / SCHEMBL2260139

SCHEMBL2260139

SCHEMBL2260139

FC(F)(F)c1ncc(Cl)cc1Br

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PLAU P00749 1/20 0.42
▸ HTT P42858 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ ENPP3 O14638 1/20 0.34
▸ ENPP1 P22413 1/20 0.34
▸ ATF1 P18846 2/20 0.33
▸ NFKB1 P19838 2/20 0.33
▸ PDK2 Q15119 1/20 0.33
▸ GLA P06280 1/20 0.32
▸ IDO1 P14902 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21718409 0.79 PLAU (0.42) PLAUHTTHSD17B10L3MBTL1
SCHEMBL17964135 0.78 HTT (0.43) PLAUHTTHSD17B10L3MBTL1ATF1
SCHEMBL2256015 0.78 KMT2A (0.46) HTTIDO1ALDH1A1
SCHEMBL25584916 0.77 HTT (0.42) HTTHSD17B10L3MBTL1ATF1NFKB1
SCHEMBL19778533 0.77 GRM4 (0.30) —
SCHEMBL25599692 0.77 HTT (0.42) HTTHSD17B10L3MBTL1ATF1NFKB1
SCHEMBL29743287 0.77 HTT (0.42) HTTHSD17B10L3MBTL1ATF1NFKB1
SCHEMBL29698226 0.77 GRM4 (0.30) —
SCHEMBL440236 0.76 — —
SCHEMBL25297018 0.75 CCR1 (0.34) PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 — — US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 — — US disclosed
WO-2025072395-A1 TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-04-03 — — WO disclosed
EP-3498693-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2024-10-30 — — EP disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 — — US disclosed
US-20240058457-A1 BTK DEGRADER NEWAVE PHARMACEUTICAL INC. (US) 2024-02-22 — — US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 — — US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 — — CN disclosed
EP-4263552-A1 BTK DEGRADER Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) 2023-10-25 — — EP disclosed
WO-2023122093-A1 REV-ERB AGONISTS FOR TH17-MEDIATED INFLAMMATORY DISORDERS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-06-29 — — WO disclosed
US-20140194410-A1 THIOLACTAMS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-10 — — US disclosed
US-8507667-B2 Thiolactams and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-08-13 — — US disclosed
US-20120309743-A1 THIOLACTAMS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-12-06 — — US disclosed
US-20120302551-A1 THIOLACTAMS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-11-29 — — US disclosed
US-8268992-B2 Thiolactams and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-09-18 — — US disclosed
US-20110257157-A1 THIOLACTAMS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-10-20 — — US disclosed
EP-2373657-A1 5, 7-DIHYDRO- 6H-PYRIMIDO Ý 5, 4-D¨Ý 1¨BENZAZEPIN-6-THIONES AS PLK INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-10-12 — — EP disclosed
US-7998952-B2 Thiolactams and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-08-16 — — US disclosed
US-20100179126-A1 THIOLACTAMS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-07-15 — — US disclosed
WO-2010065134-A1 5, 7-DIHYDRO- 6H-PYRIMIDO [ 5, 4-D] [ 1 ] BENZAZEPIN-6-THIONES AS PLK INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PLAU 381/4885HTT 1359/4885HSD17B10 1464/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 PLAU 381/4885HTT 1359/4885HSD17B10 1464/4885
US-20120302551-A1 THIOLACTAMS AND USES THEREOF PLK3, PLK4, PLK2 PLAU 1466/4885HTT 2989/4885HSD17B10 1959/4885
US-20100179126-A1 THIOLACTAMS AND USES THEREOF PLK3, PLK4, PLK2 PLAU 1466/4885HTT 2989/4885HSD17B10 1959/4885
US-20110257157-A1 THIOLACTAMS AND USES THEREOF PLK3, PLK4, PLK2 PLAU 1466/4885HTT 2989/4885HSD17B10 1959/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH PLAU 3434/4885HTT 1417/4885HSD17B10 2859/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 PLAU 1419/4885HTT 462/4885HSD17B10 1492/4885
US-20240058457-A1 BTK DEGRADER BTK, LYN, SYK PLAU 3747/4885HTT 3163/4885HSD17B10 2022/4885
US-20140194410-A1 THIOLACTAMS AND USES THEREOF PLK3, PLK4, PLK2 PLAU 1466/4885HTT 2989/4885HSD17B10 1959/4885
US-20120309743-A1 THIOLACTAMS AND USES THEREOF PLK3, PLK4, PLK2 PLAU 1466/4885HTT 2989/4885HSD17B10 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.